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Despite intensive therapy, acute lymphoblastic leukemia (ALL) relapse is still a major cause of 
cancer-related death in children and the survival of children with lymphoid blast crisis chronic 
myeloid leukemia (CML-LyBC) is even worse.1,2 Further improvements in outcome, achieved 
by dose optimization and combination therapy, have stagnated due to chemotherapy related 
toxicity.3 Therefore, new treatment options are warranted to further improve the cure rates of 
these children. 
Leukemia is the net result of genetic alterations (including point mutations, rearrangements, 
deletions, and copy number alterations), epigenetic alterations, and / or microenvironmental 
abnormalities in hematopoietic stem and progenitor cells.4-6 These alterations ultimately result 
in the deregulation of kinase-mediated signal transduction pathways; intracellular signaling 
cascades involving protein phosphorylation events catalyzed by active kinases.7,8 As the 
malignant transformation of cells highly depends on these deregulated intracellular signaling 
pathways, protein kinases are an attractive target for cancer therapy. 
The introduction of kinase inhibitors for the treatment of CML has profoundly changed the 
outcome from a fatal disease to a leukemic subtype with a favorable prognosis.9 This marks 
the beginning of a new era of cancer therapy. Over the past decades, genome profiling has 
vastly increased our understanding of oncogenesis and revealed genetic alterations currently 
treated with specific kinase inhibitors, for example, ALK translocations and EGFR mutations 
in non-small-cell lung cancer and BRAF mutations in melanoma.10-12 Unfortunately, intensive 
genome profiling has not yet resulted in the wide implementation of kinase inhibitors for the 
treatment of ALL and CML-LyBC, other than kinase inhibitors targeting BCR-ABL. As changes 
in signal transduction pathways are the net result of genomic, epigenomic, and environmental 
alterations, the aim of this thesis is to identify potential druggable targets by generating insights 
in active signal transduction pathways in pediatric lymphoid leukemias. 
The implementation of kinase inhibitors in the clinic for the treatment of pediatric malignancies 
experiences significant limitations. In Chapter 2 we provided a short overview of currently used 
strategies for the implementation of kinase inhibitors as well as reasons why kinase inhibitors 
has unfortunately not yet resulted in the widespread use for the treatment of pediatric cancer. 
These reasons include, problems with pediatric drug testing, the complexity of cancer, and 
resistance to kinase inhibitors. Lastly, we argue that using a personalized medicine strategy 
combining kinomics, proteomics, and drug screens can bridge the gap between pediatric 
cancers and the use of kinase inhibitors. In this approach, after initial tumor characterization, 
kinome and proteome profiling will be performed on patient samples, as well as subject patient 
cells to a drug screen including multiple kinase inhibitors (either FDA approved or in the pipelines 
of pharmaceutical companies) to characterize their patient specific cancer profile. Integrating 
these results will define rational combination therapies. In order to determine treatment effects 
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on signaling, kinome and proteome profiles will be re-determined after in vitro treatment with 
potential combination therapies. Ultimately, data integration will result in a comprehensive 
network of primary signaling pathways, suitable targets for therapy, and drug induced bypass 
mechanisms.
Previously, we used kinase activity profiling to identify interesting signaling hubs, as well as new 
potential druggable targets by generating more insights in signal transduction pathways.13-15 
In Chapter 3 we have employed this technique to provide novel insight into active signal 
transduction pathways in pediatric ALL and we identified several signaling proteins relevant for 
ALL pathogenesis and of potential interest for future targeted therapy approaches. In total, we 
identified 250 commonly phosphorylated peptides, which could be aligned to well-known signal 
transduction pathways downstream of the precursor B-cell receptor (pre-BCR) and precursor 
T-cell receptor alpha (pre-TCRA) e.g. the MAPK pathway and the PI3K/Akt pathway, as well as 
regulators of the cell cycle including components of the p53 and Rb1 signaling pathways. For 
27 peptides, differential phosphorylation between BCP-ALL and T-ALL was observed. Among 
these, BTEB2_S163, CD2_Y281, p73_Y99, OPN_S148, CDX2_S60, and TrkA_Y496 have been 
previously found to be associated with ALL. To provide a proof of principle for our approach 
we selected one lead of the list of commonly activated peptides (HGFR_Y1235, also known as 
c-Met) in order to test its efficacy as a potential target. Despite high peptide phosphorylation 
intensities in all primary ALL samples, c-Met protein expression could not be detected in any 
of the four ALL cell lines examined. Since the peptide derived from HGFR_Y1235 is related to 
sequences corresponding to other proteins including RON (MST1R), we examined RON protein 
expression and showed that knockdown of RON decreased leukemic cell growth and survival 
of ALL cell lines. Altogether, Chapter 3 shows that kinome profiling is an elegant approach to 
study kinase activity by peptide phosphorylation which allows rapid identification of known 
and unknown signaling proteins relevant to ALL. Furthermore, our list of commonly activated 
peptides will guide future research into specific proteins as well as targeting options. 
In chapter 3 we showed that phosphorylation of a cyclic (c)-AMP response element binding 
protein (CREB) derived peptide containing residue serine 133 was among the most strongly 
phosphorylated peptides in the ALL samples. Moreover, the CREB_S133 peptide was more 
highly phosphorylated in T-ALL compared to BCP-ALL (P = 0.024). In Chapter 4 we studied 
the role of CREB as a potential target for treatment in ALL. CREB phosphorylation and mRNA 
levels showed that CREB expression was significantly higher in ALL compared to normal 
bone marrow (NBM, phosphorylation: P < 0.0001, mRNA: P = 0.004). In our small pediatric 
cohort, we observed that patients with high CREB phosphorylation levels trended towards 
a lower event-free survival relative to patients with low phosphorylation levels (P = 0.073). In 
a larger cohort of mostly young adults, high CREB and CREB_S133 levels were correlated 
with a lower median overall survival compared to patients with normal or below normal levels. 
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ShRNA mediated knockdown of CREB in ALL cell lines resulted in dramatically decreased cell 
growth that appeared to be the net result of changes in cell cycle distribution and the induction 
of apoptosis. Gene expression profiling was performed to explain the observed phenotypic 
effects. Consistent with a role for CREB in the regulation of cell proliferation, we observed 
gene expression changes in known CREB target genes regulating cell cycle, apoptosis, 
and cell proliferation. Interestingly however, within the list of downregulated genes, enzymes 
involved in glycolysis (GPI, ALDOC, and PKM2), TCA cycle (DLAT and IDH3A), and serine and 
glycine biosynthesis (PHGDH, PSAT1, and SHMT2) were among the most prominent. The 
downregulation of these essential genes likely contributes to the observed phenotypic effects 
observed in response to CREB knockdown. Similar to CREB knockdown, the CREB inhibitor 
KG-501 decreased leukemic cell viability and induced apoptosis in ALL cell lines, as well as 
primary T-ALL samples, with cases showing high CREB phosphorylation levels being more 
sensitive than those with lower phospho-CREB levels. Together, the in vitro findings of this study 
support an important role for CREB in the survival of ALL cells and identify this transcription 
factor as a potential target for treatment in ALL. 
Genome wide approaches in ALL have aenlarged the list of risk predictors and included 
IKZF1 deletions as an unfavorable prognostic factor.16-18 IKZF1 deletions can be identified in 
approximately 70% of the children with Philadelphia chromosome positive (Ph+) ALL and in 
10-15% of the children with Philadelphia chromosome negative (Ph-) ALL. Although IKZF1 
deletions in children are most commonly found in a Ph- background, the effect of IKZF1 deletions 
on signaling pathways in Ph- ALL have not been extensively studied. Therefore, in Chapter 5 
we aimed to study the effect of IKZF1 deletions on active signal transduction pathways using 
kinome profiling. Kinase activity profiles of 31 IKZF1 wild type patients and 14 patients harboring 
an IKZF1 alteration (13 deletions and 1 gain) were generated. Unsupervised hierarchical cluster 
analysis showed no clustering based upon IKZF1 status, karyotype, or other copy number 
alterations. Thirty-nine peptides were differentially phosphorylated between IKZF1 deleted and 
IKZF1 wild type pediatric Ph- BCP-ALL patients. Nevertheless, absolute differences of peptide 
phosphorylation intensities between IKZF1 deleted and wild type samples were small. To focus 
more closely on active signal transduction pathways, we determined peptide phosphorylation 
of proteins involved in important signaling pathways for BCP-ALL cell proliferation and survival 
(e.g. the BCR signaling pathway, the MAPK, PI3K/Akt/mTOR, JAK/STAT5 signaling pathways), 
adhesion pathways, and regulators of the cell cycle. Comparing phosphorylation intensities of 
peptides associated with these main signaling pathways showed no differences in pathway 
activation between the two groups. In addition to the kinome profiles, we performed western 
blot analysis of 14 pediatric BCP-ALL samples. These western blot results showed large 
variations in phosphorylation levels between the different ALL samples, independent of IKZF1 
status. Based on these results we conclude that although IKZF1 deletions appear to be an 
important clinical prognostic factor, we were unable to identify a unique IKZF1 dependent 
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protein expression signature in pediatric Ph- ALL and consequently no specific targets for future 
therapy of Ph- IKZF1 deleted BCP-ALL could be identified.
With the introduction of tyrosine kinase inhibitors (TKIs), CML has transformed from a fatal 
disease to a leukemia subtype with a favorable prognosis.9 However, once a blast crisis (BC) 
has occurred, treatment options are limited in the terms of months.2 Therefore, early recognition 
of patients at risk of developing a BC is desirable. In the Chapter 6 we used Multiplex Ligation-
dependent Probe Amplification (MLPA) analysis to screen for the presence of copy number 
alterations (CNAs) in a large cohort of pediatric CML cases in order to investigate whether B-cell 
lymphoid leukemia specific copy number alterations (CNAs, e.g. IKZF1, PAX5, and CDKN2A 
deletions) could be detected in pediatric CML-CP and used to predict disease progression to 
LyBC. Copy number alterations were detectable in material from one of the CML-AP and in 
all of the CML-LyBC patients, while no CNAs were found in any of the 77 CML-CP samples. 
Recurrent deletions at time of CML-LyBC were found in IKZF1, PAX5, and the CDKN2A/B 
locus. Based on this study, we conclude that clonal CNAs are rare or even absent in pediatric 
CML-CP but are a hallmark of disease progression.
The activation of signaling pathways, independent of BCR-ABL1 activity, might be involved in 
disease progression to CML-LyBC and CML-LyBC cell survival. Previous studies have described 
a roll for Akt, STAT3, and FAK activation in the development of imatinib resistance in CML, 
with a subsequent higher risk of progression to blast crisis.19-24 In Chapter 7 we have studied 
the role of Akt, STAT3, and FAK for the survival of CML-LyBC cells to identify new potential 
therapeutic targets. Phosphorylation of these three targets was highly variable between four 
CML-LyBC cases, and consistently, differential effects of target inhibition on cell survival were 
seen. Nevertheless, these preliminary results show that the direct use of kinase inhibitors 
might be suitable for the treatment of CML-LyBC, guided by kinase activity profiles in individual 
patients. This further emphasizes the need for personalized approaches to identify patient-
specific targets for therapy. Hence, to extend on these preliminary observations, kinome and 




GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Kinase activity profiling
Deregulated intracellular kinase-mediated signal transduction pathways are implicated in the 
genesis and maintenance of cancer either by stimulating growth (e.g. increased cell survival 
and cell growth) or by contributing to resistance to therapy.5-7,25 Kinases are enzymes catalyzing 
protein phosphorylation by transferring phosphate groups from adenosine triphosphate (ATP) 
to specific proteins. Kinases can acquire tumor-promoting capacities by genetic alterations 
including mutations and translocations that give rise to constitutive active kinases.8 These 
constitutive active kinases have proven to be very effective targets for targeted therapy with 
small molecule inhibitors as shown for BCR-ABL1 positive chronic myeloid leukemia (CML), ALK-
rearranged non-small cell lung cancer (NSCLC), and BRAF mutated melanoma.9-12 In addition 
to these cancer subtypes with known “driver” mutations, intracellular kinase-mediated signal 
transduction pathways are required for malignant transformation in all cancer types. Therefore, 
kinases have become one of the most intensively targeted class of enzymes for therapy.26
In this thesis we aimed to identify therapeutic targets by generating insight into active signal 
transduction pathways in pediatric lymphoid leukemias using high-throughput kinase activity 
profiling. Active signal transduction pathways were determined in various ALL subtypes including 
BCP-ALL and T-ALL (chapter 3) and in IKZF1 wild type versus deleted BCP-ALL (chapter 5). 
This in vitro array enables kinases in the sample lysate to phosphorylate peptides derived from 
known phosphorylation sites from human protein sequences. In this thesis kinome profiling 
generated insight into active signal transduction pathways in ALL including the activation of 
the well-known signaling pathways MAPK and PI3K/Akt downstream of the pre-BCR and 
pre-TCRA and regulators of the cell cycle/p53 pathway, as well as the identification of targets 
previously described in either BCP-ALL or T-ALL. In addition, we created a list of targets of 
potential interest for future therapy approaches in pediatric ALL. This list includes growth factor 
receptors, intracellular kinases of different signaling pathways, and transcription factors. The 
validity of our approach was shown with the identification of RON and CREB as attractive targets 
for future investigations. Despite these promising results, as with other approaches, we came 
across several limitations. First of all, kinase activity profiling is an in vitro approach without 
spatiotemporal regulation mechanisms and the tertiary structure of phosphorylation sites causing 
the relationship between in vitro data and the in vivo situation not to be 1:1 comparable.27 
Moreover, since we are using peptide sequences of approximately 11 amino acids in length, 
sensitivity and specificity of each individual target peptide e.g. which individual kinase recognizes 
a target peptide and how efficiently the kinase phosphorylates that peptide is largely unknown.28 
Additionally, it is difficult to find a peptide substrate specific to one kinase.29 As we experienced 
in chapter 3 where we observed phosphorylation of the peptide derived from c-Met despite 
undetectable membrane and intracellular c-Met protein expression, cross-phosphorylation 
might occur making validation experiments required to confirm novel kinome data findings. 
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This issue might be overcome by combining individual peptide phosphorylation events, rather 
than evaluating individual peptides.29 Another disadvantage of kinome profiling is that this 
approach only provides information about end point phosphorylation events. Consequently, 
this readout gives limited information about slowed down or accelerated reactions, which are 
frequent processes in treatment responses or oncogenesis, respectively. For the future, the 
use of peptide arrays may be improved by measuring kinetic phosphorylation rates rather 
than end point measurements, as already implemented in the Pamgene microarrays.29 Finally, 
data interpretation and data processing are still a major challenge to fully explore the wealth of 
information acquired by kinome profiling.27,28 In this thesis we studied peptide phosphorylation 
instead of upstream kinase activity since peptide sequences are correlated with a variable 
amount of upstream kinases and the interference of spot intensities into in vivo upstream 
kinase activity is not straightforward.13,26,27 In addition, we generated an overview of active signal 
transduction pathways in pediatric acute lymphoblastic leukemia by creating a disease network 
based on known protein-protein interactions of the commonly activated peptides according to 
the STRING database and annotated these peptides to known signal transduction pathways 
using the KEGG and PhosphoSite pathway databases. Using these databases, kinome profiling 
results are implemented in a context of known biological information. However, by the use of 
mathematical and computational models for the analyses of network interpretation, kinome 
profiling might also be able to provide new biological data.28,30 This will be an important goal to 
reach in the near future resulting in a comprehensive use of all the information kinome profiling 
may provide. In conclusion, peptide arrays are able to provide detailed insights in the dynamics 
of intracellular signaling pathways and the complexity of cancer cells, as shown in this thesis. 
When these results can be combined with data from all different omics technologies such as 
genomics and transcriptomics using inventive bioinformatics programs, the impact of the data 
will be even stronger.31,32 
Receptor tyrosine kinases and transcription factors as putative druggable 
targets
In our list of commonly activated peptides we noticed several growth factor receptors (chapter 
3). Although receptor tyrosine kinase inhibitors (RTKIs) have been implemented in the treatment 
of specific solid tumors, FDA approved inhibitors targeting various receptor tyrosine kinases 
e.g. sorafenib, crizotinib, and lapatinib are not yet used for the treatment of leukemias. Although 
evidence from literature is limited, expression of several receptor tyrosine kinases has been 
reported in leukemia and targeting these receptors was shown to be effective, alone or combined 
with conventional therapies, in the treatment of ALL.33-35 For example, EGFR2 (ErbB2) is 
expressed in approximately 30% of the patients with BCP-ALL and in vitro inhibition of EGFR2 
reduces cell proliferation especially when combined with BCR-ABL tyrosine kinase inhibitors in 
Ph+ ALL.33 Additionally, upregulation of RTK-ligand levels has been frequently observed following 
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kinase inhibition and is able to activate downstream intracellular signaling pathways to induce 
therapy resistance.36,37 These results, in combination with our kinome profiling results, show 
that although mutations in receptor tyrosine kinases are rare in leukemias, compounds directed 
at these targets might be of potential interest in the treatment of leukemia.
In addition to receptor tyrosine kinases and intracellular kinases, several transcription factors 
including CREB, Bcl-2, c-Myc, and NF-kappaB were found in our list of commonly activated 
peptides (chapter 3). Transcription factors have traditionally been considered too difficult 
to target and pharmacological inhibition of transcription factors is usually achieved by the 
inhibition of upstream phosphokinases or endogeneous ligands.38-41 However, targeting 
upstream phosphokinases lacks specificity because of the multiple downstream effects of 
one single intracellular kinase and its numerous feedback loops.38 Consequently, targeting 
transcription factors is likely to be a more specific approach, but targeting the interaction 
between DNA-binding proteins and DNA using inhibitors is technically challenging.38,42,43 It 
has been hypothesized that targeting the protein-protein interactions of transcription factors 
with their co-activators, as for KG-501 the CREB inhibitor we used in chapter 4, might be a 
pharmaceutical possibility to target transcription factors.38,44 Since pharmacological inhibition of 
protein-protein interactions are likely to represent one of the next major classes of therapeutic 
targets, drugs targeting transcription factors are approaching and may be of greater importance 
in the near future.38 
Targeted therapy: from bench to bedside
Preclinical models 
Since the discovery of imatinib for CML, cancer research has been focused on the identification 
of new therapeutic targets for the treatment of other malignancies. Validation of these targets 
in cancer cell lines is usually one of the initial steps in drug development. Cell line models are 
easy to handle and manipulate, show reproducible results, and are an inexpensive model to 
test a large number of potential drugs before committing to large scale in vivo trials.45,46 In 
addition to the use of cell lines for cytotoxic assays to determine drug sensitivity patterns, 
cell lines can also be used to study drugs’ mechanisms of action and can be used for the 
research of signaling pathway adaptations in response to anticancer drugs.47-49 Although human 
cancer derived cell lines are the most widely used models to test therapeutic strategies, the 
limitations of cell line models are well known.49,50 For example, since not all cancer types can 
grow indefinitely in vitro, those that do grow have acquired new mutations that allow these 
cells to adapt to their artificial environment.51 Furthermore, cell lines do not recapitulate the 
molecular heterogeneity of human tumors.52 Improving the preclinical evaluation of targeting 
compounds, focusing on effectivity and toxicity, is necessary and of great importance since 
only about 5% of the identified putative anticancer compounds demonstrate sufficient clinical 
activity in phase III trials.52,53 Although animal models are essential to study the effects of newly 
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identified drugs, improvements of in vitro models that more closely mimic tumor heterogeneity 
as well as the in vivo tumor microenvironment will be the first step. This will be challenging 
since acute lymphoblastic leukemia cells cannot be sufficiently cultured in vitro, despite specific 
culture medium supplemented with growth factors including cytokines, FLT3-ligand, and stem 
cell factor. Attempts to improve in vitro models for the culture of primary ALL cells might 
include, for example, a culture system mimicking the bone marrow niche including optimal 
oxygen levels and cell-cell and cell-stroma contact, like a hydrogel-based 3D-culture system 
of mesenchymal stromal cells.54-56 
Clinical trial design for targeted therapy
In addition to improvements of preclinical study models, the design of traditional clinical trials 
also needs to be adapted to kinase inhibitors.57,58 Traditionally, phase I trials are performed to 
identify a maximum tolerated dose and side effects which can be used into phase II trials to 
determine drug activity. In contrast to conventional cytotoxic drugs, the relationship between 
target effect and toxicity may not be linear for kinase inhibitors.57,59 Kinase inhibitors may have 
a plateau in effect, meaning a higher dose will not improve clinical efficacy and consequently 
patient benefit.57,59 Additionally, kinase inhibitors do not necessarily induce toxicity in healthy 
tissues.57,59 Therefore, the aim of phase I clinical trials using kinase inhibitors should be to 
identify the optimal biological dose. This is defined as the dose at which there is maximal 
inhibition of the target with acceptable toxicity.57 Safety, side effects, pharmacokinetics, and 
pharmacodynamics should be documented at that dose.57,58 As the primary end point will be 
target inhibition, enrolling patients with different forms of cancer is feasible.58 Obviously, as 
kinase inhibitors target specific kinases, trials should include only patients that express the 
target. Summarizing, insights in the mechanisms underlying oncogenesis have changed the 
paradigm of cancer treatment with promising results of kinase inhibitors in the laboratory. In 
the next years we should further improve the design of preclinical models by optimizing in vitro 
culture systems and clinical trials by defining new adapted study objectives to successfully 
introduce these new types of drugs into the clinic.  
Challenges in targeted cancer therapy
Despite the success of imatinib for the treatment of CML, the clinical translation of kinase 
inhibitors for the treatment of patients has been sub-optimal.25 Drug resistance to kinase 
inhibitors by cell-intrinsic mechanisms, the cross-talk of cancer cells with their microenvironment, 
and tumor heterogeneity are major challenges when considering the use of targeted therapy 




As outlined in chapter 2, several mechanisms of drug resistance have been described.25,37 
First of all, acquired mutations might cause resistance to kinase inhibitors in mainly two ways; 
(1) mutations altering the target, for example kinase domain mutations, confer resistance by 
decreasing the efficiency of the inhibitor and (2) new mutations may activate alternative survival 
pathways and circumvent the inhibitory effect of a given drug. 
Secondly, therapy resistance can be mediated by dynamic reprogramming e.g. alternated 
routes of kinase pathway activation in response to pharmacological disturbance.37 Alternated 
activation of kinase-dependent signaling pathways might either be upstream or downstream 
of the target pathway or by the activation of bypass signaling pathways.25 Additionally, the 
microenvironment might activate survival signaling pathways by cell adhesive interactions or 
by the secretion of soluble growth factors or cytokines.25,36,61,62 Therapy resistance by dynamic 
reprogramming may be defeated by simultaneous inhibition of the primary pathway as well 
as the bypass pathway (combination therapy). Previously, we have shown that a combination 
of kinome and proteome profiling is able to predict signaling pathway adaptations and can 
be used to define rational combination therapies.15 This observation might be valuable for 
future approaches to improve the clinical success rate of kinase inhibitors with a pivotal role 
for signaling dynamics. In chapter 2 we argue that using a personalized medicine strategy can 
improve the implementation of kinase inhibitors. In order to minimize the occurrence of dynamic 
reprogramming, the patient specific signaling profile will need to be established both at time of 
diagnosis and after the in vitro treatment of selected combination therapies to determine basal 
signal transduction activity as well as drug induced signaling. Data integration will ultimately 
result in a more comprehensive view of active signal transduction pathways during treatment, 
including potential bypass mechanisms.
Tumor heterogeneity
Inter- and intratumor heterogeneity add an additional level of complexity to the understanding 
of cancer. Intertumor heterogeneity was documented using genome-wide analysis subdividing 
acute lymphoblastic leukemia in various subtypes with diverse kinase-activating lesions, making 
targeted therapy approaches only appropriate for specific subtypes.63 Evaluating intertumor 
heterogeneity at the level of drug sensitivity, is even more complex than initially hypothesized 
based on the various genetic subtypes. As signaling dynamics is the net result of genomic, 
epigenetic, and microenvironmental abnormalities, drug sensitivity patterns to kinase inhibitors 
showed heterogeneous results within genetic subgroups.64-66 In chapter 5 we performed kinome 
profiling in IKZF1 deleted BCP-ALL patients to identify potential targets for the treatment of 
this ALL subtype. Although IKZF1 deletions are an independent clinical prognostic factor, 
no IKZF1 distinct protein expression profile could be established using kinome profiling and 
western blot analysis.16-18 Suggesting that within predefined ALL subtypes, in chapter 5 patients 
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harboring IKZF1 deletions, heterogeneous subgroups exist. Similarly, intertumor heterogeneity 
was seen in lymphoid blast crisis CML, where we observed various drug responses among 
different CML-LyBC cases (chapter 7). Intertumor heterogeneity challenges the implementation 
of kinase inhibitors into the clinic since subpopulations suited for specific targeted therapies 
must be determined accurately and clinical trials based on the “one-size-fits-all” strategy 
are in general disappointing. Although we have analyzed the kinome profile results within 
predefined subgroups, results might also be analyzed individually and patients may be classified 
according to patient specific signaling profiles. This would enable the identification of patients 
with similar signaling dynamics including specific targets for therapy instead of targets of 
potential interest for entire ALL subtypes. As we have observed an overlap of active signal 
transduction pathways within different subtypes of cancer and drug screen approaches showed 
no complete segregation based upon leukemia types.65 It might be interesting to perform 
kinome and proteome analyses in a large cohort of various pediatric malignancies. Such an 
analysis will be able to determine signaling dynamics heterogeneity, as well as similarities 
within various malignancies to evaluate signaling specific potential druggable targets instead 
of disease specific targets based on signaling.
Next to intertumor heterogeneity, intratumor heterogeneity potentially represents the greatest 
challenge to deliver effective personalized cancer therapy.25,60,67 Intratumor heterogeneity 
develops in space and time, leading to a complex mix of clones.25,60 Subclonal diversity was 
also reported in ALL, showing ALL as a heterogeneous disease at diagnosis and varying 
over time continuously with the development and progression of disease.68 In the majority 
of the ALL cases, relapses arise from the emergence of a minor subclone through a genetic 
evolution following Darwinian logic by different responses to antileukemic therapy.60,69,70 Single-
cell sequencing allows a better understanding of intratumor heterogeneity required to clarify 
the events mediating cancer formation, treatment resistance, and the implementation of clonal 
specific molecular targets.71 The effects of genetic heterogeneity on the heterogeneity at the 
protein level are largely unknown. Single cell proteomic approaches such as single-cell western 
blotting are extremely challenging, but upcoming.72 Nevertheless, it has been hypothesized 
that heterogeneity at the protein level of cancer cells is less complex than could be expected 
from genetic heterogeneity.73,74 Especially, since all of the 138 known driver genes can be 
classified into one or more of 12 co-operating pathways.75 With the current techniques single-
cell kinome profiling is not yet available to study the effect of genomic intratumor heterogeneity 
on the level of kinome profiles. However, by redeterming kinome and proteome profiles after 
in vitro treatment with kinase inhibitors or combinational treatment, the signaling dynamics of 
therapy resistant subclones will become more prominent in this second overview; providing 




Systems biology to guide future personalized medicine
As illustrated by the pitfalls of current targeted therapies, cancer is an extremely complex 
disease and this complexity remains a major challenge for the implementation of individualized 
medicines into the clinic. It has been hypothesized that system biology approaches can manage 
and model this complexity through the integration of cellular signaling networks between 
cells, stroma, organs, and the entire organism.32,67 Cancer systems biology aims to develop 
effective predictive models for the validations of new therapies and drugs by analyzing how 
the intracellular networks of normal cells are disturbed during oncogenesis.67 For example, 
mathematical modeling can integrate the evolutionary nature of individual cancer genomes to 
analyze and predict the dynamics of heterogeneous tumor populations on therapy response.67,76 
Since cancer is a multi-factorial disease, comprising genetic, transcriptional, epigenetic, and 
signaling alterations, information from one layer can be used to infer alterations in another layer.32 
Therefore, cancer systems biology might play a central role in future personalized medicine. 
CONCLUSIONS
Despite the great efforts made to identify targets for the treatment of lymphoid leukemias, the 
clinical implementation of targeted drugs remains a challenge. This thesis describes the use 
of kinome profiling for the identification of potential therapeutic targets in lymphoid leukemias. 
Based on the obtained kinome profiles we established a number of putative druggable targets, 
of which RON and CREB were validated by in vitro studies. Although the implementation of 
targeted therapy remains challenging due to cancer complexity, ongoing developments of 
high-throughput techniques combined with systems biology should facilitate the selection of 
therapeutic targets with the ultimate goal to cure every child with lymphoid leukemia. 




1.   Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc 
Hematol Educ Program 2012; 2012: 389-396. 
2.  Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant 
patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22: 2176-2183. 
3.   Roberts KG and Mullighan CG. How new advances in genetic analysis are influencing the understanding 
and treatment of childhood acute leukemia. Curr Opin Pediatr 2011; 23: 34-40. 
4.   Passegue E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias 
a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A 2003; 
100 Suppl 1: 11842-11849. 
5.   Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. 
6.   Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674. 
7.   Vogelstein B and Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-
799. 
8.   Blume-Jensen P and Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365. 
9.  Hehlmann R, Hochhaus A, Baccarani M, European LeukemiaNet. Chronic myeloid leukaemia. Lancet 
2007; 370: 342-350. 
10.  Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced 
non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet 
Oncol 2011; 12: 1004-1012. 
11.  Sequist LV, Martins RG, Spigel D, et al. First-line gefitinib in patients with advanced non-small-cell 
lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-2449. 
12.  Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. 
N Engl J Med 2010; 363: 809-819. 
13.  Sikkema AH, Diks SH, den Dunnen WF, et al. Kinome profiling in pediatric brain tumors as a new 
approach for target discovery. Cancer Res 2009; 69: 5987-5995. 
14.   Ter Elst A, Diks SH, Kampen KR, et al. Identification of new possible targets for leukemia treatment 
by kinase activity profiling. Leuk Lymphoma 2011; 52: 122-130. 
15. Kampen KR, Ter Elst A, Mahmud H, et al. Insights in dynamic kinome reprogramming as a consequence 
of MEK inhibition in MLL-rearranged AML. Leukemia 2014; 28: 589-599. 
16.  Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. 
N Engl J Med 2009; 360: 470-480. 
17.  Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated 
pediatric precursor B-ALL. Leukemia 2010; 24: 1258-1264. 
18.   van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature 
and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 
2013; 122: 2622-2629. 
19.   Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T. Phosphatidylinositol-3 kinase inhibitors 
enhance the anti-leukemia effect of STI571. Oncogene 2002; 21: 5868-5876. 
20.  Kharas MG and Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation 
and downstream effectors. Cancer Res 2005; 65: 2047-2053. 
21.   Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase 
activation causing imatinib-resistance. J Hematol Oncol 2011; 4: 6-8722-4-6. 
Chapter 8
150
22.  Bewry NN, Nair RR, Emmons MF, et al. Stat3 contributes to resistance toward BCR-ABL inhibitors in 
a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008; 7: 3169-3175. 
23.  Eiring AM, Page BD, Kraft IL, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic 
lethality in therapy-resistant chronic myeloid leukemia. Leukemia 2015; 29: 586-597.
24.  Glodek AM, Le Y, Dykxhoorn DM, et al. Focal adhesion kinase is required for CXCL12-induced 
chemotactic and pro-adhesive responses in hematopoietic precursor cells. Leukemia 2007; 21: 
1723-1732. 
25.   Ramos P and Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for 
resistance. Oncogene 2015; 34: 3617-3626. 
26.   Piersma SR, Labots M, Verheul HM, Jimenez CR. Strategies for kinome profiling in cancer and potential 
clinical applications: chemical proteomics and array-based methods. Anal Bioanal Chem 2010; 397: 
3163-3171. 
27.  Sikkema AH, den Dunnen WF, Diks SH, Peppelenbosch MP, de Bont ES. Optimizing targeted cancer 
therapy: towards clinical application of systems biology approaches. Crit Rev Oncol Hematol 2012; 
82: 171-186. 
28.   Arsenault R, Griebel P, Napper S. Peptide arrays for kinome analysis: new opportunities and remaining 
challenges. Proteomics 2011; 11: 4595-4609. 
29.  Versele M, Talloen W, Rockx C, et al. Response prediction to a multitargeted kinase inhibitor in cancer 
cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout. Mol 
Cancer Ther 2009; 8: 1846-1855. 
30.  Boja ES and Rodriguez H. Proteogenomic convergence for understanding cancer pathways and 
networks. Clin Proteomics 2014; 11: 22-0275-11-22. eCollection 2014. 
31.  Parikh K and Peppelenbosch MP. Kinome profiling of clinical cancer specimens. Cancer Res 2010; 
70: 2575-2578. 
32.   Du W and Elemento O. Cancer systems biology: embracing complexity to develop better anticancer 
therapeutic strategies. Oncogene 2015; 34: 3215-3225. 
33.  Irwin ME, Nelson LD, Santiago-O’Farrill JM, et al. Small molecule ErbB inhibitors decrease proliferative 
signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. 
PLoS One 2013; 8: e70608. 
34.   Schult C, Dahlhaus M, Ruck S, et al. The multikinase inhibitor Sorafenib displays significant 
antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic 
cells. BMC Cancer 2010; 10: 560-2407-10-560. 
35.  Tsai LH, White L, Raines E, et al. Expression of platelet-derived growth factor and its receptors by 
two pre-B acute lymphocytic leukemia cell lines. Blood 1994; 83: 51-55. 
36.  Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to 
anticancer kinase inhibitors. Nature 2012; 487: 505-509. 
37.  Duncan JS, Whittle MC, Nakamura K, et al. Dynamic reprogramming of the kinome in response to 
targeted MEK inhibition in triple-negative breast cancer. Cell 2012; 149: 307-321. 
38.  Fontaine F, Overman J, Francois M. Pharmacological manipulation of transcription factor protein-protein 
interactions: opportunities and obstacles. Cell Regen (Lond) 2015; 4: 2-015-0015-x. eCollection 
2015. 
39.   Mayr B and Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. 
Nat Rev Mol Cell Biol 2001; 2: 599-609. 
40.   Caboni L and Lloyd DG. Beyond the ligand-binding pocket: targeting alternate sites in nuclear 
receptors. Med Res Rev 2013; 33: 1081-1118. 
Summary, discussion, and future perspectives
151
8
41.   Redmond AM and Carroll JS. Defining and targeting transcription factors in cancer. Genome Biol 
2009; 10: 311-2009-10-7-311. Epub 2009 Jul 24. 
42.  Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription 
factors: function, expression and evolution. Nat Rev Genet 2009; 10: 252-263. 
43.  Darnell JE,Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2: 740-749. 
44.   Best JL, Amezcua CA, Mayr B, et al. Identification of small-molecule antagonists that inhibit an 
activator: coactivator interaction. Proc Natl Acad Sci U S A 2004; 101: 17622-17627. 
45.  Burdall SE, Hanby AM, Lansdown MR, Speirs V. Breast cancer cell lines: friend or foe? Breast Cancer 
Res 2003; 5: 89-95. 
46.  van Staveren WC, Solis DY, Hebrant A, et al. Human cancer cell lines: Experimental models for cancer 
cells in situ? For cancer stem cells? Biochim Biophys Acta 2009; 1795: 92-103. 
47.  Nakatsu N, Yoshida Y, Yamazaki K, et al. Chemosensitivity profile of cancer cell lines and identification 
of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. 
Mol Cancer Ther 2005; 4: 399-412. 
48.  Vargo-Gogola T and Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 
2007; 7: 659-672. 
49.   Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of 
candidate anticancer agents. Nat Rev Cancer 2010; 10: 241-253. 
50.   Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst 2013; 
105: 452-458. 
51.  Borrell B. How accurate are cancer cell lines? Nature 2010; 463: 858. 
52.   Ocana A, Pandiella A, Siu LL, Tannock IF. Preclinical development of molecular-targeted agents for 
cancer. Nat Rev Clin Oncol 2010; 8: 200-209. 
53.   Begley CG and Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature 
2012; 483: 531-533. 
54.   Sharma MB, Limaye LS, Kale VP. Mimicking the functional hematopoietic stem cell niche in vitro: 
recapitulation of marrow physiology by hydrogel-based three-dimensional cultures of mesenchymal 
stromal cells. Haematologica 2012; 97: 651-660. 
55.  Jing D, Fonseca AV, Alakel N, et al. Hematopoietic stem cells in co-culture with mesenchymal stromal 
cells--modeling the niche compartments in vitro. Haematologica 2010; 95: 542-550. 
56.   Jing D, Wobus M, Poitz DM, et al. Oxygen tension plays a critical role in the hematopoietic 
microenvironment in vitro. Haematologica 2012; 97: 331-339. 
57.   Mussai FJ, Yap C, Mitchell C, Kearns P. Challenges of clinical trial design for targeted agents against 
pediatric leukemias. Front Oncol 2015; 4: 374. 
58.   Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. 
Genes Dev 2003; 17: 2998-3010. 
59.   Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist 2002; 7: 401-409. 
60.  Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev 
Cancer 2012; 12: 323-334. 
61.   Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to 
minimal residual disease. Nat Rev Cancer 2009; 9: 665-674. 
62.  Puissant A, Dufies M, Fenouille N, et al. Imatinib triggers mesenchymal-like conversion of CML cells 
associated with increased aggressiveness. J Mol Cell Biol 2012; 4: 207-220. 
Chapter 8
152
63.   Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute 
lymphoblastic leukemia. N Engl J Med 2014; 371: 1005-1015. 
64.   Tyner JW, Deininger MW, Loriaux MM, et al. RNAi screen for rapid therapeutic target identification in 
leukemia patients. Proc Natl Acad Sci U S A 2009; 106: 8695-8700. 
65.   Tyner JW, Yang WF, Bankhead A,3rd, et al. Kinase pathway dependence in primary human leukemias 
determined by rapid inhibitor screening. Cancer Res 2013; 73: 285-296. 
66.   Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments 
for patients with chemorefractory acute myeloid leukemia. Cancer Discov 2013; 3: 1416-1429. 
67.   Werner HM, Mills GB, Ram PT. Cancer Systems Biology: a peek into the future of patient care? Nat 
Rev Clin Oncol 2014; 11: 167-176. 
68.   Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating 
cells in leukaemia. Nature 2011; 469: 356-361. 
69.   Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute 
lymphoblastic leukemia. Science 2008; 322: 1377-1380. 
70.   Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat 
Rev Cancer 2006; 6: 924-935. 
71.   Gawad C, Koh W, Quake SR. Dissecting the clonal origins of childhood acute lymphoblastic leukemia 
by single-cell genomics. Proc Natl Acad Sci U S A 2014; 111: 17947-17952. 
72. Hughes AJ, Spelke DP, Xu Z, et al. Single-cell western blotting. Nat Methods 2014; 11: 749-755. 
73.  Turtoi A, Blomme A, Castronovo V. Intratumoral heterogeneity and consequences for targeted 
therapies. Bull Cancer 2015; 102: 17-23. 
74.   Turtoi A, Blomme A, Debois D, et al. Organized proteomic heterogeneity in colorectal cancer liver 
metastases and implications for therapies. Hepatology 2014; 59: 924-934. 
75.  Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013; 
339: 1546-1558. 
76.  Almendro V, Cheng YK, Randles A, et al. Inference of tumor evolution during chemotherapy by 
computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep 
2014; 6: 514-527. 


